Literature DB >> 16953542

Hairy cell leukemia.

Claire Dearden1, Monica Else.   

Abstract

Hairy cell leukemia is a rare B-cell neoplasm. When treated with either pentostatin or cladribine, complete and durable remissions can be secured and life expectancy for most patients is normal. A small minority of patients require alternative treatment with monoclonal antibodies or immunotoxins. Patients who attain a complete response to first-line treatment have the best prognosis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16953542     DOI： 10.1007/s11912-006-0055-z

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  49 in total

1.  Splenectomy vs. alpha interferon: a randomized study in patients with previously untreated hairy cell leukemia.

Authors:  R V Smalley; J Connors; R L Tuttle; S Anderson; W Robinson; J K Whisnant
Journal:  Am J Hematol       Date:  1992-09       Impact factor: 10.047

2.  Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience.

Authors:  M S Tallman; D Hakimian; A W Rademaker; C Zanzig; E Wollins; E Rose; L C Peterson
Journal:  Blood       Date:  1996-09-15       Impact factor: 22.113

3.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors:  R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

4.  Hairy cell leukemia: clinical presentation and follow-up of 211 patients.

Authors:  G Flandrin; F Sigaux; G Sebahoun; P Bouffette
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

5.  Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.

Authors:  H Hagberg; L Lundholm
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

6.  Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years.

Authors:  Monica Else; Rosa Ruchlemer; Nnenna Osuji; Ilaria Del Giudice; Estella Matutes; Anthony Woodman; Andrew Wotherspoon; John Swansbury; Claire Dearden; Daniel Catovsky
Journal:  Cancer       Date:  2005-12-01       Impact factor: 6.860

7.  Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

Authors:  M A Hoffman; D Janson; E Rose; K R Rai
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

8.  Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.

Authors:  I W Flinn; K J Kopecky; M K Foucar; D Head; J M Bennett; R Hutchison; W Corbett; P Cassileth; T Habermann; H Golomb; K Rai; E Eisenhauer; F Appelbaum; B Cheson; M R Grever
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

9.  Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia.

Authors:  Mia Thorsélius; Sarah H Walsh; Ulf Thunberg; Hans Hagberg; Christer Sundström; Richard Rosenquist
Journal:  Leuk Res       Date:  2005-02       Impact factor: 3.156

10.  Pentostatin induces durable remissions in hairy cell leukemia.

Authors:  P A Cassileth; B Cheuvart; A S Spiers; D P Harrington; F J Cummings; R S Neiman; J M Bennett; M J O'Connell
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544
View more
  1 in total

Review 1.  Long-term follow-up after purine analogue therapy in hairy cell leukaemia.

Authors:  Monica Else; Claire E Dearden; Daniel Catovsky
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.